Glenmark Pharma gets final USFDA nod for generic version of Abiraterone Acetate tabs
PTI, May 20, 2022, 10:19 AM IST
New Delhi: Glenmark Pharmaceuticals Ltd on Friday said its US arm has received final approval from the US health regulator for its generic version of Abiraterone Acetate tablets used for the treatment of prostate cancer.
The approval granted by the US Food and Drug Administration (USFDA) to Glenmark Pharmaceuticals Inc, USA (Glenmark) is for Abiraterone Acetate tablets of strength of 500 mg, the company said in a statement.
It is the generic version of Zytiga tablets, 500 mg, of Janssen Biotech Inc, it added.
Citing IQVIA sales data for the 12-month period ended March 2022, the company said Zytiga tablets 500 mg achieved annual sales of approximately USD 260.2 million.
Glenmark said its current portfolio consists of 173 products authorized for distribution in the US marketplace and 49 abbreviated new drug applications pending approval with the USFDA.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
Mangaluru: Campco opposes WHO’s claim of arecanut being carcinogenic
10 month baby gets new heart, new life
World COPD Day: Know your lung function
As Delhi chokes with dangerous pollution levels, doctors warn of health risks for all
World Diabetes Day 2024: Kasturba Hospital Manipal Hosts Zumba Session at Malpe Beach to Raise Diabetes Awareness
MUST WATCH
Latest Additions
Ruling Cong sweeps Assembly bypolls in Karnataka, setback to BJP-JD(S) alliance
Delhi Police arrests ‘proclaimed offender’ from Mumbai
No row over Maharashtra CM’s post; leaders of Mahayuti will decide: Fadnavis
Delhi Police arrests ‘proclaimed offender’ from Mumbai
Pant may go for higher than Rs 25 crore, owners would not want to miss his X-factor: Raina
Thanks for visiting Udayavani
You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.